Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

Lymphoma Clinical Trial

Official title:

Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using RFT5-SMPT-dgA,Specific Anti-IL-2 Receptor Immunotoxin: Reducing GVHD Risk Associated With HLA-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in Older Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00025662
• Other study ID #: 010162
• Secondary ID: 01-H-0162
• Status: Completed
• Phase: Phase 2
• First received: October 11, 2001
• Last updated: December 9, 2011
• Start date: May 2001
• Est. completion date: February 2008

Study information

• Verified date: December 2011
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and effectiveness of stem cell transplantation in which the donors T lymphocytes have undergone "selective depletion." Certain patients with cancers of the blood undergo transplantation of donated stem cells to generate new and normally functioning bone marrow. In addition to producing the new bone marrow, the donor's T-lymphocytes also fight any tumor cells that might have remained in the body. This attack on tumor cells is called a "graft-versus-leukemia" (GVL) effect. However, another type of T-lymphocyte from the donor may cause what is called "graft-versus-host-disease" (GVHD), in which the donor cells recognize the patient's cells as foreign and mount an immune response to reject them. Selective depletion is a technique that was developed to remove the T-lymphocytes that cause harmful GVHD, while keeping those that produce the desirable GVL effect.

Description:

Despite improved prophylaxis and treatment, graft-versus-host disease (GVHD) remains a major complication after allogeneic stem cell transplantation. Although the most effective way to prevent GVHD is T cell depletion, this process results in poor immune function leading to increased rates of relapse, graft rejection, and post-transplant infections. Ideally, a method of removing GVHD-producing effector cells while retaining a broad T cell repertoire, including preservation of 3rd party, antiviral and anti-tumor responses would be desirable. Preclinical studies from our lab have demonstrated that alloreactive T cells can be selectively removed from the donor lymphocyte pool in vitro with the use of a specific immunotoxin directed against the interleukin-2 receptor.

To test this clinically, we will perform nonmyeloablative allogeneic stem cell transplants in older patients with hematologic malignancies. Although these patients can be cured with this approach, they have significant morbidity and mortality from GVHD. At our institution, nonmyeloablative transplantation is associated with an incidence of grade II-IV acute GVHD of approximately 50%. Although well tolerated in younger patients, patients over the age of 50 years have a transplant-related mortality (TRM) of approximately 35%, which is mostly related to GVHD. Through selective depletion of alloreactive donor lymphocytes, we hope to reduce GVHD mortality, while preserving the transplant efficacy.

Patients receive a reduced intensity preparative regimen, followed by a mobilized peripheral blood stem cell allograft from an HLA-identical sibling donor, containing "selectively-depleted" donor lymphocytes. To obtain such a graft, G-CSF-mobilized peripheral blood from the donor undergoes a positive CD34 selection followed by a negative T cell selection using the Nexell Isolex 300i system. This stem cell-rich, T cell-depleted product will contain a CD34+ cell dose of at least 5x10(6)/kg. The unabsorbed fraction, remaining after the positive CD34 selection, is then co-cultured for 72 hours with irradiated lymphocytes from the patient. The immunotoxin, RFT5-SMPT-dgA, is added during the last 24 hours of culture to remove alloreacting cells. The washed T cell product (CD3+ cell dose of 1-4 x 10(8)/kg) is cryopreserved. Following the preparative regimen, the patient receives successive infusions of the stem cell product and selected lymphocytes. All patients receive standard post transplant immunosuppression with cyclosporine for a minimum of 30 days, followed by dose reduction depending on the degree of donor lymphocyte chimerism.

The primary end point of this study is the incidence and severity of acute GVHD. We will also examine the incidence of chronic GVHD, engraftment, degree of donor-host chimerism, transplant related morbidity and mortality, as well as disease-free and overall survival. Stopping rules will minimize the risk of untoward or unexpected side effects.

Other known NCT identifiers

• NCT00016484

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: February 2008
• Est. primary completion date: February 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

• INCLUSION CRITERIA - PATIENT

• Ages 50-75 years.

• Relapsed CML in chronic or accelerated phase after therapy with STI-571 (Gleevec).

• Acute lymphoblastic leukemia (ALL), all patients in complete or partial remission. Exceptions: T cell ALL.

• Acute myelogenous leukemia (AML): AML in first complete or partial remission including AML secondary to chemotherapy or prior hematological disease such as myelodysplastic syndrome, and myeloproliferative disorder. Exceptions: AML with good risk karyotypes: AML M3 t(5;17), AML M4Eo (inv. 16), AML t(8;21). All AML in second or subsequent complete remission.

• Myelodysplastic syndromes: (1) refractory anemia with excess of blasts (RAEB), (2) refractory anemia with excess blasts in transformation (RAEBT), (3) MDS with poor risk cytogenetics defined by a complex karyotype (greater than or equal to three anomalies) or chromosome 7 abnormalities, (4) secondary MDS after prior cytotoxic or radiation therapy, or (5) chronic myelomonocytic leukemia (CMML).

• Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia, refractory to nucleoside analog therapy, with either progressive bulky disease or anemia (less than 10 g/dl) or thrombocytopenia (less than 100,000/microliter) not due to recent chemotherapy.

• Mantle cell lymphoma;

• Relapsed intermediate- or high-grade non-Hodgkin's lymphoma: (1) post autologous marrow or PBSC transplant, or (2) chemorefractory relapse. Exceptions: T cell NHL.

• Relapse Hodgkin's disease: (1) post autologous marrow or PBSC transplant, or (2) chemorefractory relapse.

• Low-grade follicular or small lymphocytic lymphoma: (1) relapsed following conventional chemotherapy, (2) relapsed following autologous marrow or PBSC transplant, or (3) chemoresistant disease.

• Life expectancy greater than 3 months.

• Ability to comprehend the investigational nature of the study and provide informed consent.

• Availability of an HLA-identical family donor, 18 to 75 years old.

• INCLUSION CRITERIA - DONOR:

• HLA identical family donor, 18 to 75 years old.

• Fit to receive G-CSF and give peripheral blood stem cells (normal blood count, normotensive, no history of stroke, no history of severe heart disease).

• Ability to comprehend the investigational nature of the study and provide informed consent.

• EXCLUSION CRITERIA RECIPIENT:

• Pregnant or lactating.

• ECOG performance status of 3 or more.

• Major anticipated illness or organ failure incompatible with survival from PBSC transplant.

• DLCO less than 60% predicted.

• Left ventricular ejection fraction less than 40%, or any angina.

• Absolute lymphocyte count less than 300/mm(3).

• Serum creatinine greater than 2.5 mg/dl.

• Serum bilirubin greater than 4 mg/dl, transaminases greater than 5x upper limit of normal.

• HIV positive.

• Other malignant diseases liable to relapse or progress within 2 years.

• EXCLUSION CRITERIA DONOR:

• Pregnant or lactating.

• HIV positive. Donors who are positive for HBV, HCV or HTLV will be used at the discretion of the investigator and with appropriate consent of the recipient.

• Donor unfit to receive G-CSF and undergo apheresis (uncontrolled hypertension, history of heart failure or unstable angina, platelet count less than 90,000/cu mm).

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Graft vs Host Disease
• Hodgkin Disease
• Leukemia
• Leukemia, Lymphocytic
• Leukemia, Lymphoid
• Leukemia, Myeloid
• Leukemia, Myelomonocytic, Chronic
• Lymphoma
• Lymphoma, Mantle-cell
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Preleukemia

Intervention

Drug:
• RFT5-SMPT-dgA
A specific anti-interleukin-2 receptor immunotoxin
• Nexell Isolex system
CD34 selection/ T cell depletion used this system

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Barrett J, Solomon S. The transition from bench to bedside: lessons learned in the creation of a new T-cell product for the clinic. Cytotherapy. 2004;6(6):593-5. — View Citation

Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy. 2005;7(2):109-15. Review. — View Citation

Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman SF, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett AJ. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the — View Citation

Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Ghetie V, Michálek J, Mavroudis D, Read EJ, Vitetta ES, Barrett AJ. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy. 2002;4(5):395-406. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment-related Mortality	Nonrelapse mortality in the first 100 days of transplant expressed as a percentage of the total subjects.; This is different from outcome measure 3 (Cumulative Nonrelapse Mortality), which is cumulative non relapse mortality till December 2011.	100 days after stem cell infusion	Yes
Secondary	Overall Survival	Percent overall survival (actuarial) at analysis in Dec 2011.	Dec 2011.	No
Secondary	Cumulative Non Relapse Mortality	Percent non relapse mortality (actuarial) at analysis in Dec 2011	Dec 2011.	Yes

External Links

•   NIH Clinical Center Detailed Web Page